Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aconite Pain Oil for prevention and treatment of chemotherapy-induced polyneuropathy
2022-502889-24-00Phase 3Authorised
- Sponsor
- WALA Heilmittel GmbH
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Aconit Schmerzöl with Placebo (refined peanut oil) (2 arms). Primary endpoint: Time to occurrence of CIPN. Planned start Oct 2023; status: authorised.
02
Drugs
Aconit Schmerzöl
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on 2022-502889-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502889-24-00.